Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease

Phosphodiesterase 10A (PDE10A), the enzyme which catalyzes hydrolysis of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), is located almost exclusively in striatal γ-amino-butyric acid (GABA)ergic medium spiny neurons (MSNs). Since dopaminergic deficiency in Parkinson...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of pharmacology 2021-11, Vol.910, p.174460-174460, Article 174460
Hauptverfasser:	Lenda, Tomasz, Ossowska, Krystyna, Berghauzen-Maciejewska, Klemencja, Matłoka, Mikołaj, Pieczykolan, Jerzy, Wieczorek, Maciej, Konieczny, Jolanta
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antiparkinson Agents - pharmacology Antiparkinson Agents - therapeutic use Disease Models, Animal GABAergic Neurons - drug effects Humans L-DOPA Levodopa - pharmacology Levodopa - therapeutic use Male Oxidopamine - administration & dosage Oxidopamine - toxicity Parkinson Disease, Secondary - chemically induced Parkinson Disease, Secondary - diagnosis Parkinson Disease, Secondary - drug therapy Parkinson Disease, Secondary - pathology Parkinson's disease PDE10A inhibitor Phosphodiesterase Inhibitors - pharmacology Phosphodiesterase Inhibitors - therapeutic use Phosphoric Diester Hydrolases - metabolism Rats Rotation Sensorimotor deficits Severity of Illness Index Unilateral rat model
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!